

R H I N O M E D

ASX: RNO

A TECHNOLOGY PLATFORM

CHANGING THE WAY THE WORLD BREATHES

MASTER INVESTOR UK 2018


IMPORTANT NOTICE

This document contains certain forward-looking statements, relating to Rhinomed Limited's (Rhinomed) business which can be identified by the use of forward looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of the company's technologies and products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales. In particular, managements expectations regarding the approval and commercialization of the technology could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and business prospects. Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

ONE IN FOUR PEOPLE STRUGGLE TO BREATHE THROUGH THEIR NOSE

COMPROMISING SLEEP AND RESPIRATION

- Nasal obstruction is a contributor to snoring and poor sleep
- Mouth breathing can lead to poor sleep and Sleep Disordered Breathing issues
- Poor sleep and snoring is now being directly linked to Alzheimer and other neurocognitive disorders
- People with nasal congestion are twice as likely to have moderate to severe sleep apnea



LEVERAGING PHYSICS TO ADDRESS NASAL OBSTRUCTION


- The diameter of your nose matters
- A small change in the radius of the nose can dramatically impact the volume of air entering the airway.
- **Poiseuille's Law** - if the radius of the nose increases by 1, the volume of air traveling through the airway increases 16 times (the power of 4).
- Rhinomed's technology leverages Poiseuille's Law to deliver a significant improvement in nasal patency and efficacy

Proprietary ratchet mechanism that delivers perfect individualised fit



Dilates from the back of the nose minimising pressure on the septum

Designed to mold to the internal surface of the nostril



Rhinomed technology provides greater airflow into the upper airway


MUTE - A LEADING GLOBAL CONSUMER HEALTH BRAND

- Adjustable for each nostril to ensure ultimate comfort and fit
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- Reusable up to 10 times, thus small, medium & large pack lasts 30 days
- RRP US\$24.95 delivering strong margins
- Winner - 2018 US Drugstore Excellence Awards




DELIVERING YEAR ON YEAR GROWTH

- #67 in the 2017 FT1000: High Growth Companies Asia-Pacific
- Total units shipped FY17 YTD - approx. 150,000
- FY17 Revenue generated from installed store base of approximately 2800 stores




DELIVERING QUARTER ON QUARTER GROWTH

Calendar year 2017 Performance




DELIVERING YEAR ON YEAR STORE GROWTH

Global Retail Footprint (stores)




- 3x increase in store count
- Footprint in Australia, UK, Canada and USA
- FY 18 Target footprint of 15,000 stores

IN THE USA WE STARTED 2017 WITH 1000 STORES




WE STARTED 2018 WITH 5500+ STORES NATIONWIDE AND GROWING



A REVOLUTIONARY TECHNOLOGY PLATFORM

DISRUPTING THE US\$8BILLION DECONGESTION MARKET



MUTE 'CLEAR'

- Mute with added 'menthol/ eucalypt' formulation
- Next generation multi formulation platform
- Delivers low dose, overnight nasal decongestant
- Disruptive innovation in a market Vicks has dominated for decades
- Design being finalised and production scoping underway

DISRUPTING THE US\$3BILLION AROMATHERAPY MARKET

MUTE 'DEEP SLEEP'

- Mute with added 'lavender/chamomile' formulation
- Delivers low dose, overnight nasal relaxant to tackle anxiety, sleep onset and poor sleep maintenance
- Disruptive delivery technology in the aromatherapy market
- Class 1 product – regulatory process scoped
- Design being finalised and production scoping underway



INPEAP – A DISRUPTIVE, LOW INVASIVE SOLUTION FOR OBSTRUCTIVE SLEEP APNEA

- IntraNasal Expiratory Positive Airway Pressure (INPEAP)
- A new patented alternative to CPAP and mandibular advancement technologies
- Targeting the 70% of OSA patients with Mild to moderate OSA - (AHI 14-29)
- Internal nasal delivery of Positive Expiratory Airway Pressure to keep airway open during sleep
- Low invasive solution when compared to CPAP and Oral devices
- Successfully completed Phase 1 trial showing:
 - Nasally delivered EPAP
 - Well tolerated, 73% compliance
 - Program derisked through the growing acceptance of Mute



NEXT GENERATION NASAL DRUG DELIVERY



Opening up an entirely new nasal drug delivery opportunity.

A novel and patented drug delivery platform providing unique patients benefits and powerful product differentiation.

- Low dose, long release and/or quick onset
- Instant removal in case of side effect
- Multiple deliverable modes and dosage options
- Innovative platform for multiple targets
- Existing solutions significantly de-risk acceptance driving strong compliance
- Potential Targets:
 - Cannabinoids for pain relief and sleep
 - Triptans for Migraine
- Actively seeking partnerships

DELIVERING ON MAJOR MILESTONES AND POISED FOR GROWTH

1

EXCITING PLATFORM TECHNOLOGY

1. Two products already in market
2. Multiple next generation technology applications

2

COMPREHENSIVE IP PORTFOLIO

1. Over 60 patents granted and pending
2. 57 Design patents
3. Brands and trademarks

3

ESTABLISHED SCIENCE AND R&D PROGRAM

1. Leveraging existing research in role of the nose and respiration
2. Positive Phase 1 Trial results for Obstructive Sleep Apnea Therapy

4

SIGNIFICANT OPPORTUNITY TO SCALE GLOBALLY

1. Already on shelf in over 8000 stores in Aust, UK, Canada and USA
2. Business development pipeline of 15,000+ stores in US alone
3. Opportunity for global retail expansion

5

GROWING REVENUE LINES

1. Strong existing retail channels
2. Well established production and logistic network
3. Strong gross margins

6

COMPELLING CONSUMER HEALTH BRANDS IN GROWING GLOBAL MARKETS

1. Turbine - global sport and exercise market
2. Mute - OTC consumer health and sleep markets
3. Emerging interest as companion therapy in existing sleep apnea market

***“I'm a huge fan of your product. It has changed my life!
I sleep like a baby and run like an iron man.”***

- Charles, Customer

WHO IS RHINOMED

GLOBALLY EXPERIENCED BOARD OF DIRECTORS

Mr Ron Dewhurst - Chairman	Previously Head of Americas JP Morgan Asset Management, EVP Head of Global Investment Managers Legg Mason Inc, CEO IOOF Holdings Ltd. Currently Director OneVue Ltd, Sprott Inc.
Mr Michael Johnson – CEO and Managing Director	CEO and MD since February 2013, Director Cogentum Advisory, Previously Director Cetus Energy, Principal Strategyn
Mr Brent Scrimshaw - Non Exec Director	Previously VP & CEO Nike Western Europe, VP & CMO Nike Europe, Middle East & Africa, GM Nike USA (East), CMO Nike Australia and NZ. Currently Non Exec Director Catapult Ltd (ASX: CAT) and CEO Unscript'd Pty Ltd
Dr Eric Knight - Non Exec Director	Previously Lawyer Baker McKenzie, Consultant Boston Consulting Group. Currently Strategy Professor & Pro-Vice-Chancellor University of Sydney

ASX: RNO

FY17 Financial Position

Receipts FY17 - \$2.02m
Units Shipped FY17 YTD - 150,000
Strong Gross Margins
Cash in Bank - \$3m (31/12/17)


Capital Structure

Top 20 - 47%
Market Cap - approx A\$15m
Shares on issues - 117m

Offices

Melbourne, Australia
Cincinnati, USA

INVESTMENT PROPOSITION




MARKET

Compelling technology in a growing global market - Sleep
Compelling innovation Pipeline.



DISTRIBUTION

Business is rapidly expanding the revenue base through a global distribution footprint



KEY FOCUS

- USA & CANADA
- UK
- Aust/NZ Base



NEAR-TERM NEWS FLOW

- Growing number of distributors
- Partnership opportunities



COMPELLING INVESTMENT COMPARATOR

- Breathe Right™ Strips - Peak revenues of approximately US\$150m
- Purchased by GSK - US\$566m in 2007

MICHAEL JOHNSON, CEO

e. mjohnson@rhinomed.global

t. +61 3 8416 0900

www.rhinomed.global